Mr. Dane Stevens reports

OPTIMI HEALTH REPORTS FIRST MDMA-ASSISTED TREATMENTS OF 2026 ARE UNDERWAY ACROSS AN EXPANDED NETWORK OF AUSTRALIAN CLINICS

The first patients of 2026 have been treated using Optimi Health Corp.'s MDMA (3,4-methylenedioxymethamphetamine) capsules at authorised clinics across Australia, operating under the Authorised Prescriber Scheme.

The company continues to supply its finished MDMA drug product directly to authorised clinics under Australia's regulated prescribing framework, supporting continuing patient treatment programs across the country. According to aggregated information obtained through a freedom of information request to the Therapeutic Goods Administration (TGA), publicly reported data from Australia's Authorised Prescriber Scheme indicated that no serious adverse events (SAEs) were recorded among patients receiving MDMA-assisted therapy under the scheme as of Sept. 16, 2025.

More recently, the Australian Department of Veterans' Affairs (DVA) recently announced a $740-million veterans rehabilitation plan that includes support for psychedelic-assisted therapy for eligible veterans with PTSD (posttraumatic stress disorder).

"Entering 2026 with active treatments under way across a growing clinic network is an important step in the continued development of regulated MDMA-assisted therapy," said Dane Stevens, chief executive officer and co-founder of Optimi Health. "Our direct-to-clinic supply model allows us to maintain manufacturing oversight, ensure our product is cost-effective and support authorized prescribers within Australia's established regulatory framework. We believe this structure provides a scalable pathway for responsible commercial expansion."

Patient-reported outcomes (PROs) are being collected by the Australian National University (ANU) as part of an expanding real-world evidence (RWE) program focused on MDMA-assisted therapy for the treatment of PTSD.

Optimi holds a drug establishment licence issued by Health Canada that authorizes the manufacture of 60-milligram and 40-milligram MDMA capsules for regulated therapeutic use, including the treatment of PTSD, where permitted by local regulatory frameworks.

According to the Australian Bureau of Statistics, approximately 5 to 6 per cent of Australians experience PTSD in a given year, representing roughly 1.3 million to 1.5 million people, with higher prevalence among veterans and first responders.

Clinicians, hospital networks and authorized programs operating under the Authorised Prescriber Scheme may seek information regarding access through Mind Medicine Australia at ilan@mindmedicineaustralia.org.

About Optimi Health Corp.

Optimi Health is a leading producer of prescribed psychedelic treatments for mental health therapies. As a Health Canada-licensed, GMP-compliant (good manufacturing practice) pharmaceutical manufacturer producing validated MDMA and botanical psilocybin products from two 10,000-square-foot facilities in British Columbia, Optimi supplies active pharmaceutical ingredients and finished dosage forms to regulated channels, with products currently in market for prescription use in Australia through the Authorized Prescriber Scheme and accessible in Canada through the Special Access Program.

We seek Safe Harbor.